2595MO Exploratory analysis of chromophobe renal cell carcinoma in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first-line treatment.
Saved in:
| Title: | 2595MO Exploratory analysis of chromophobe renal cell carcinoma in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first-line treatment. |
|---|---|
| Authors: | Ahrens, M.1 (AUTHOR), Haanen, J.B.A.G.2 (AUTHOR), Albiges, L.3 (AUTHOR), Gross Goupil, M.4 (AUTHOR), Boleti, E.5 (AUTHOR), Gravis, G.6 (AUTHOR), Flechon, A.7 (AUTHOR), Grimm, M-O.8 (AUTHOR), Bedke, J.9 (AUTHOR), Barthelemy, P.10 (AUTHOR), Castellano Gauna, D.E.11 (AUTHOR), Mellado Gonzalez, B.12 (AUTHOR), Ivanyi, P.13 (AUTHOR), Rottey, S.14 (AUTHOR), Floercken, A.15 (AUTHOR), Suarez Rodriguez, C.16 (AUTHOR), Maroto Rey, J.P.17 (AUTHOR), Burkholder, I.18 (AUTHOR), Hartmann, A.19 (AUTHOR), Bergmann, L.20 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1392-S1392. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
